Vasocidin (soln)
| Vasocidin (soln) | |
|---|---|
| DOSAGE | 2 gtts q4hrs x 2 days, then Taper. If signs and symptoms fail to improve after two days, patients should be re-evaluated |
| GENERIC | sulfacetamide 10%, prednisolone phosphate 0.23% |
| SIZE | 5mL, 10mL |
| INDICATIONS | Sulfacetamide Sodium and Prednisolone Sodium Phosphate Ophthalmic Solution is indicated for corticosteroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. |
| MECHANISM OF ACTION | sulfonamide/corticosteroid: Sulfonamides inhibit bacterial folate synthesis. Corticosteroids inhibit the release of arachidonic acid. |
| MICROBIOLOGY | The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. This product does not provide adequate coverage against: Neisseria species, Serratia marcescens. |
| CONTRAINDICATIONS & WARNINGS | Sulfacetamide Sodium and Prednisolone Sodium Phosphate Ophthalmic Solution is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. |
| This product is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation, to other sulfonamides, or to other corticosteroids. (Hypersensitivity to the antimicrobial components occurs at a higher rate than for other components.) | |
| PEDIATRIC USE | Safety and effectiveness in pediatric patients below the age of 6 years have not been established. |
| PREGNANCY | Pregnancy Category C |
| Prednisolone has been shown to be teratogenic in rabbits, hamsters, and mice. In mice, prednisolone has been shown to be teratogenic when given in doses 1 to 10 times the human ocular dose. Dexamethasone, hydrocortisone and prednisolone were ocularly applied to both eyes of pregnant mice five times per day on days 10 through 13 of gestation. A significant increase in the incidence of cleft palate was observed in the fetuses of the treated mice. There are no adequate, well-controlled studies in pregnant women dosed with corticosteroids. | |
| Kernicterus may be precipitated in infants by sulfonamides given systemically during the third trimester of pregnancy. It is not known whether sulfacetamide sodium can cause fetal harm when administered to a pregnant woman or whether it can affect reproductive capacity. Sulfacetamide Sodium and Prednisolone Sodium Phosphate Ophthalmic Solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. | |
| NOTE | Original Vasocidin was discontinued around 2005. Now available as B&L and Falcon generics, and nearly identical to Blephamide (Allergan). Seldomly used due to low steroid concentration and poor performance of sulfacetamide |